Black Diamond Therapeutics
BDTX
69 hedge funds and large institutions have $36.3M invested in Black Diamond Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 13 closing their positions.
5% more call options, than puts
Call options by funds: $844K | Put options by funds: $807K
0.13% less ownership
Funds ownership: 59.28% → 59.15% (-0.13%)
7% less funds holding
Funds holding: 74 → 69 (-5)
31% less capital invested
Capital invested by funds: $52.9M → $36.3M (-$16.6M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
54% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.62M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$992K |
| 3 |
Millennium Management
New York
|
+$307K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$284K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$947K |
| 2 |
HCM
Hawkeye Capital Management
Miami Beach,
Florida
|
-$598K |
| 3 |
NM
Newtyn Management
New York
|
-$524K |
| 4 |
E
Ergoteles
New York
|
-$184K |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$180K |
BDTX Hedge Fund Activity: Q3 2022 in Review
69 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2022, worth a combined $36.3M — down 31% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BDTX and 8 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 12 added.
The largest buyer was K2 Principal Fund, adding an estimated $1.62M. The largest seller was Morgan Stanley, cutting an estimated $947K.
- 69 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2022, down from 74 in Q2 2022.
- Funds reported $36.3M of Black Diamond Therapeutics stock for Q3 2022, down 31% quarter-over-quarter.
- 8 funds opened new Black Diamond Therapeutics positions in Q3 2022 and 13 closed out, a net change of -5 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2022 was K2 Principal Fund, an estimated $1.62M added.
- The largest Black Diamond Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $947K sold.
Based on aggregated 13F filings for Q3 2022.